News & Updates
Filter by Specialty:
Acute kidney, liver injury risks with remdesivir pinned to underlying SARS-CoV-2 infection
Treatment with remdesivir in patients hospitalized for COVID-19 does not appear to confer increased risks of acute kidney and liver injury, with a recent study showing that these risks are already elevated even before exposure to treatment and there is no further increase following remdesivir initiation.
Acute kidney, liver injury risks with remdesivir pinned to underlying SARS-CoV-2 infection
18 Apr 2022
Early molnupiravir use benefits unvaccinated COVID-19 outpatients
Early administration (ie, within 5 days after symptom onset) of the oral, small-molecule antiviral prodrug molnupiravir slashed the risk of hospitalization or death in at-risk, unvaccinated, nonhospitalized adults with mild-to-moderate COVID-19, findings from the phase III component of the phase II/III MOVe-OUT trial have shown.
Early molnupiravir use benefits unvaccinated COVID-19 outpatients
18 Apr 2022
Obesity med cessation more likely after RYGB than sleeve gastrectomy
Patients who are on obesity-related medications before undergoing bariatric surgery may be more likely to discontinue their medications and less likely to restart them after undergoing Roux-en-Y gastric bypass (RYGB) than laparoscopic sleeve gastrectomy (LSG), a recent study has shown.
Obesity med cessation more likely after RYGB than sleeve gastrectomy
15 Apr 2022
Maintenance selinexor promising for PFS in advanced/recurrent endometrial cancer
Maintenance treatment with selinexor improved progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer who had previously received first-line chemotherapy, particularly those with endometrioid histology and wild-type p53, according to a study presented at SGO 2022.
